BrightGene Bio-Medical Technology Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Jiandong Yuan

Chief Executive Officer (CEO)

CN¥1.9m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	8.8yrs
Participación del CEO	32.2%
Permanencia media de la dirección	8.8yrs
Promedio de permanencia en la Junta Directiva	5.3yrs

Actualizaciones recientes de la dirección

Recent updates

BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Mar 01

CEO

Jiandong Yuan (53 yo)

8.8yrs

Permanencia

CN¥1,874,200

Compensación

Mr. Jiandong Yuan serves as the Chairman and General Manager of BrightGene Bio-Medical Technology Co., Ltd. (Formerly known as Borui Biopharmaceutical (Suzhou) Co., Ltd.) and is its Director since August 2...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jiandong Yuan	Chairman & GM	no data	CN¥1.87m	32.21% CN¥ 4.8b
Yuanlai Zou	Financial Director	8.8yrs	CN¥460.50k	sin datos
Nan Ding	Board Secretary	2.7yrs	CN¥417.60k	sin datos
Zhengye Wang	Deputy General Manager	8.8yrs	CN¥915.70k	sin datos
Kai Li	Deputy General Manager	8.8yrs	CN¥1.01m	sin datos

8.8yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 688166 es experimentado (8.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jiandong Yuan	Chairman & GM	8.8yrs	CN¥1.87m	32.21% CN¥ 4.8b
Rong Xu	Independent Director	6.7yrs	CN¥100.00k	sin datos
Zhang Li	Director	2.7yrs	CN¥626.60k	sin datos
Fan Hang	Director	2.7yrs	CN¥814.60k	sin datos
Yangqing Huang	Director	2.7yrs	CN¥854.00k	sin datos
Lei Su	Director	2.7yrs	sin datos	sin datos
Zheng Yan	Independent Director	6.7yrs	CN¥100.00k	sin datos
Xiaoqing Du	Independent Director	6.7yrs	CN¥100.00k	sin datos
Xing He	Chairman of the Supervisory Board	4yrs	sin datos	sin datos
Yingxian Shen	Supervisor	6.7yrs	sin datos	sin datos
Wei Cha	Supervisor	2.7yrs	sin datos	sin datos
Dazhong Lv	Director	7yrs	sin datos	sin datos

5.3yrs

Permanencia media

45yo

Promedio de edad

Junta con experiencia: La junta directiva de 688166 se considera experimentada (5.3 años de antigüedad promedio).

BrightGene Bio-Medical Technology Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

BrightGene Bio-Medical Technology Co., Ltd., Annual General Meeting, May 20, 2024

BrightGene Bio-Medical Technology Co., Ltd., Annual General Meeting, May 20, 2024

Less than half of directors are independent

Recent updates

Investor sentiment improves as stock rises 17%

BrightGene Bio-Medical Technology Co., Ltd., Annual General Meeting, May 20, 2024

BrightGene Bio-Medical Technology Co., Ltd., Annual General Meeting, May 20, 2024

BrightGene Bio-Medical Technology Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Investor sentiment improves as stock rises 19%

BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Full year 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.58 in FY 2022)

BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) announces an Equity Buyback for CNY 20 million worth of its shares.

BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) announces an Equity Buyback for CNY 20 million worth of its shares.

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 21%

Third quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.21 in 3Q 2022)

Investor sentiment improves as stock rises 22%

Investor sentiment improves as stock rises 27%

First quarter 2023 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.60 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.21 (vs CN¥0.17 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.14 in 2Q 2021)

Suzhou Hongbo Venture Capital Partnership agreed to acquire 2.42% stake in Caike (Suzhou) Biotechnology Co., Ltd. from BrightGene Bio-Medical Technology Co., Ltd. (SHSE:688166) for CNY 20 million.

BrightGene Bio-Medical Technology Co., Ltd. announced that it expects to receive CNY 222.3054 million in funding

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.12 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.10 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.08 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.41 (vs CN¥0.30 in FY 2019)

BrightGene Bio-Medical Technology Co., Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day low: CN¥43.62

New 90-day low: CN¥48.50

New 90-day high: CN¥61.50

BrightGene Bio-Medical Technology Co., Ltd. to Report Q3, 2020 Results on Oct 23, 2020

New 90-day low - CN¥51.60

First half earnings released

BrightGene Bio-Medical Technology Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad